News & Updates | Mogrify | Reprogramminng Health

FEATURED

CONTENT

Mogrify and Astellas announce collaboration to conduct research on in vivo regenerative medicine approaches to address sensorineural hearing loss

Mogrify Limited, a biopharmaceutical company transforming the lives of patients through a novel class of in vivo reprogramming therapies, and Astellas Pharma Inc., a leader in regenerative medicine, today announced that they have executed a collaborative research agreement on in vivo regenerative medicine approaches to address sensorineural hearing loss.

Find out more

Latest

NEWS

Mogrify awarded $1.1M additional funding from SBRI Healthcare

Mark Cavanagh2022-05-09T10:43:51+00:0028th January 2020|

Mogrify wins Innovation Award and Dr. Jane Osbourn, OBE receives Lifetime Achievement Award at Scrip Awards 2019

Mark Cavanagh2022-05-09T10:43:59+00:005th December 2019|

Mogrify wins Seed Stage Finance Raise of the Year at 2019 European Lifestars Awards

Mark Cavanagh2022-05-09T10:44:09+00:0020th November 2019|

Mogrify named ‘The One to Watch’ at Cambridge Independent Science and Technology Awards 2019

Mark Cavanagh2022-05-09T10:44:15+00:0031st October 2019|

Mogrify raises additional $16 million to advance its mission to transform the development of life-saving cell therapies

Mark Cavanagh2022-05-09T10:44:32+00:0014th October 2019|

Mogrify appoints Dr. Jane Osbourn, OBE as Chair

mogrifydigital2022-05-09T10:44:39+00:009th September 2019|

Load More Posts

Latest

Resources

VIEW ALL RESOURCES

VIEW ALL MEDIA FEATURES

VIEW ALL EVENTS

Follow Us On

Social Media

Mogrify ·
@Mogrify_UK

We are pleased to announce our #collaboration with @AstellasUS to conduct #research on #invivo #regenerativemedicine approaches to address sensorineural #hearingloss by generating new cochlear hair cells. Read more: https://t.co/NSx4hk0R2M #otology https://t.co/lIBSA015WE

View on Twitter

1

5

Mogrify ·
@Mogrify_UK

Attending the #ISMB2022? Connect with our #cellinformatics team at @iscb's flagship meeting on 10-14 July to learn more about our proprietary #cellularreprogramming platforms and their capacity to affect direct #transdifferentiation between any cell type.
https://t.co/Yn2QI5REys

View on Twitter

0

Mogrify ·
@Mogrify_UK

A review in Precision Clinical Medicine @OUPAcademic discusses the tumorigenicity risk of #iPSCs in vivo and methods to mitigate the risks in iPSC-derived #celltherapy. https://t.co/ExCfrPr6r1

Are there alternative #cellreprogramming strategies that could bypass #stemcells?

View on Twitter

0

FEATURED

CONTENT

Latest

NEWS

Mogrify awarded $1.1M additional funding from SBRI Healthcare

Mogrify wins Innovation Award and Dr. Jane Osbourn, OBE receives Lifetime Achievement Award at Scrip Awards 2019

Mogrify wins Seed Stage Finance Raise of the Year at 2019 European Lifestars Awards

Mogrify named ‘The One to Watch’ at Cambridge Independent Science and Technology Awards 2019

Mogrify raises additional $16 million to advance its mission to transform the development of life-saving cell therapies

Mogrify appoints Dr. Jane Osbourn, OBE as Chair

Latest

Resources

Follow Us On

Social Media

Subscribe to our

Newsletter

OUR INVESTORS

Newsletter

Quick Links

Quick Links

Get in touch